228 related articles for article (PubMed ID: 29599518)
1. Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.
Meiser B; Quinn VF; Mitchell G; Tucker K; Watts KJ; Rahman B; Peate M; Saunders C; Geelhoed E; Gleeson M; Barlow-Stewart K; Field M; Harris M; Antill YC; Susman R; Bowen MT; Mills L; Kirk J;
Eur J Hum Genet; 2018 Jul; 26(7):972-983. PubMed ID: 29599518
[TBL] [Abstract][Full Text] [Related]
2. When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.
Meiser B; Quinn VF; Gleeson M; Kirk J; Tucker KM; Rahman B; Saunders C; Watts KJ; Peate M; Geelhoed E; Barlow-Stewart K; Field M; Harris M; Antill YC; Mitchell G
Eur J Hum Genet; 2016 Nov; 24(11):1517-1523. PubMed ID: 27329735
[TBL] [Abstract][Full Text] [Related]
3. Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial.
Quinn VF; Meiser B; Kirk J; Tucker KM; Watts KJ; Rahman B; Peate M; Saunders C; Geelhoed E; Gleeson M; Barlow-Stewart K; Field M; Harris M; Antill YC; Cicciarelli L; Crowe K; Bowen MT; Mitchell G
Genet Med; 2017 Apr; 19(4):448-456. PubMed ID: 27684037
[TBL] [Abstract][Full Text] [Related]
4. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
Watts KJ; Meiser B; Mitchell G; Kirk J; Saunders C; Peate M; Duffy J; Kelly PJ; Gleeson M; Barlow-Stewart K; Rahman B; Friedlander M; Tucker K;
BMC Cancer; 2012 Jul; 12():320. PubMed ID: 22838957
[TBL] [Abstract][Full Text] [Related]
5. Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer.
Zilliacus E; Meiser B; Gleeson M; Watts K; Tucker K; Lobb EA; Mitchell G
Support Care Cancer; 2012 Nov; 20(11):2949-58. PubMed ID: 22441502
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.
Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW
Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064
[TBL] [Abstract][Full Text] [Related]
7. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
[TBL] [Abstract][Full Text] [Related]
8. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
9. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
[TBL] [Abstract][Full Text] [Related]
10. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
Høberg-Vetti H; Eide GE; Siglen E; Listøl W; Haavind MT; Hoogerbrugge N; Bjorvatn C
Acta Oncol; 2019 Feb; 58(2):175-181. PubMed ID: 30334464
[TBL] [Abstract][Full Text] [Related]
11. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
12. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
[TBL] [Abstract][Full Text] [Related]
13. Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery.
Shapira R; Turbitt E; Erby LH; Biesecker BB; Klein WMP; Hooker GW
Fam Cancer; 2018 Oct; 17(4):485-493. PubMed ID: 29209897
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
Metcalfe KA; Price MA; Mansfield C; Hallett DC; Lindeman GJ; Fairchild A; Posner J; Friedman S; Snyder C; ; Lynch HT; Evans DG; Narod SA; Liede A
Br J Cancer; 2020 Jul; 123(2):268-274. PubMed ID: 32393849
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
[TBL] [Abstract][Full Text] [Related]
16. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
17. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
[TBL] [Abstract][Full Text] [Related]
18. There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.
Meiser B; Gleeson M; Kasparian N; Barlow-Stewart K; Ryan M; Watts K; Menon D; Mitchell G; Tucker K
Gynecol Oncol; 2012 Jan; 124(1):153-7. PubMed ID: 22032838
[TBL] [Abstract][Full Text] [Related]
19. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
Kwong A; Chu AT
Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
